Browse PCDH7

Summary
SymbolPCDH7
Nameprotocadherin 7
Aliases BH-Pcdh; PPP1R120; protein phosphatase 1, regulatory subunit 120; BH-protocadherin (brain-heart); BHPCDH; br ......
Chromosomal Location4p15
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cell membrane; Single-pass type I membrane protein.
Domain PF00028 Cadherin domain
PF08266 Cadherin-like
PF08374 Protocadherin
Function

-

> Gene Ontology
 
Biological Process GO:0002576 platelet degranulation
GO:0006887 exocytosis
GO:0007156 homophilic cell adhesion via plasma membrane adhesion molecules
GO:0045055 regulated exocytosis
GO:0098742 cell-cell adhesion via plasma-membrane adhesion molecules
Molecular Function -
Cellular Component GO:0030141 secretory granule
GO:0030659 cytoplasmic vesicle membrane
GO:0030667 secretory granule membrane
GO:0031091 platelet alpha granule
GO:0031092 platelet alpha granule membrane
GO:0099503 secretory vesicle
> KEGG and Reactome Pathway
 
KEGG -
Reactome R-HSA-109582: Hemostasis
R-HSA-76002: Platelet activation, signaling and aggregation
R-HSA-114608: Platelet degranulation
R-HSA-76005: Response to elevated platelet cytosolic Ca2+
Summary
SymbolPCDH7
Nameprotocadherin 7
Aliases BH-Pcdh; PPP1R120; protein phosphatase 1, regulatory subunit 120; BH-protocadherin (brain-heart); BHPCDH; br ......
Chromosomal Location4p15
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between PCDH7 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolPCDH7
Nameprotocadherin 7
Aliases BH-Pcdh; PPP1R120; protein phosphatase 1, regulatory subunit 120; BH-protocadherin (brain-heart); BHPCDH; br ......
Chromosomal Location4p15
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of PCDH7 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolPCDH7
Nameprotocadherin 7
Aliases BH-Pcdh; PPP1R120; protein phosphatase 1, regulatory subunit 120; BH-protocadherin (brain-heart); BHPCDH; br ......
Chromosomal Location4p15
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of PCDH7 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.0840.898
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.4250.815
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.4680.708
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.2760.675
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.0390.987
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.6780.819
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.590.329
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-0.4890.789
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.660.735
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.0370.95
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.9010.218
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.4960.0405
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of PCDH7 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14177.107.10.452
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 103100101
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27737.42.74.70.294
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27597.43.440.587
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21174.804.81
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)8612.5012.51
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91633.3033.30.0365
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59400400.11
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47250250.364
1329033130MelanomaallAnti-PD-1 (nivolumab) 382703.7-3.70.415
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 161407.1-7.10.467
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolPCDH7
Nameprotocadherin 7
Aliases BH-Pcdh; PPP1R120; protein phosphatase 1, regulatory subunit 120; BH-protocadherin (brain-heart); BHPCDH; br ......
Chromosomal Location4p15
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of PCDH7. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolPCDH7
Nameprotocadherin 7
Aliases BH-Pcdh; PPP1R120; protein phosphatase 1, regulatory subunit 120; BH-protocadherin (brain-heart); BHPCDH; br ......
Chromosomal Location4p15
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of PCDH7. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by PCDH7.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolPCDH7
Nameprotocadherin 7
Aliases BH-Pcdh; PPP1R120; protein phosphatase 1, regulatory subunit 120; BH-protocadherin (brain-heart); BHPCDH; br ......
Chromosomal Location4p15
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of PCDH7. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolPCDH7
Nameprotocadherin 7
Aliases BH-Pcdh; PPP1R120; protein phosphatase 1, regulatory subunit 120; BH-protocadherin (brain-heart); BHPCDH; br ......
Chromosomal Location4p15
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of PCDH7 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolPCDH7
Nameprotocadherin 7
Aliases BH-Pcdh; PPP1R120; protein phosphatase 1, regulatory subunit 120; BH-protocadherin (brain-heart); BHPCDH; br ......
Chromosomal Location4p15
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between PCDH7 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolPCDH7
Nameprotocadherin 7
Aliases BH-Pcdh; PPP1R120; protein phosphatase 1, regulatory subunit 120; BH-protocadherin (brain-heart); BHPCDH; br ......
Chromosomal Location4p15
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting PCDH7 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.